On these grounds, we further explored the axonal growth pathway (PI3K/AKT/GSK-3/CRMP-2) to gain an insight into the possible repair mechanisms underlying TSTT treatment following ischemic stroke. The gene discussed is AKT1; the disease is ischemic stroke.